2020
577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy
Perreault S, Schiffer M, Zhao J, McManus D, Foss F, Gowda L, Isufi I, Seropian S, Topal J. 577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy. Open Forum Infectious Diseases 2020, 7: s353-s354. PMCID: PMC7776791, DOI: 10.1093/ofid/ofaa439.771.Peer-Reviewed Original ResearchSurveillance blood culturesBlood culturesGVHD patientsSteroid therapyDay mortalitySurveillance culturesPositive culturesHematopoietic stem cell transplant patientsGraft Versus Host DiseaseStem cell transplant patientsBlood culture positivity rateYale-New Haven HospitalSymptoms of GVHDVersus Host DiseaseCell transplant patientsNumber of patientsLack of symptomsCulture positivity rateDiagnosis of infectionNew Haven HospitalRisk of infectionCoagulase-negative staphylococciActive GVHDHost diseaseMedian doseAttenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinib
2018
2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?
Ahmad H, Perreault S, McManus D, Foss F, Isufi I, Seropian S, Topal J. 2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand? Open Forum Infectious Diseases 2018, 5: s746-s746. PMCID: PMC6255683, DOI: 10.1093/ofid/ofy210.2140.Peer-Reviewed Original ResearchVaccination seriesHSCT patientsDisease relapseCommon reasonHematopoietic stem cell transplant patientsCompliance ratePost-vaccination antibody responseStem cell transplant patientsYale-New Haven HospitalAdult HSCT patientsAutologous HSCT patientsIncomplete vaccination seriesPost-transplant vaccinationPost-vaccination titersCell transplant patientsVaccine-preventable infectionsLoss of immunogenicityNew Haven HospitalYears of ageImmunization adherenceMaintenance chemotherapyRoutine revaccinationHost diseaseImmunosuppressive therapyPrimary endpoint